The microvoa: enhancing the viral outgrowth assay (VOA) with microtechnology
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN272201600021C
- Awardee
-
Salus Discovery LLC UEI YJ6CYLKZ4JL9
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $298,743
Award facts
- Opportunity
-
- SBIRPHS20161 Solicitation number
- A Low Cost Integrated Method for Isolation of M. Tuberculosis DNA from Raw Sputum Award Notice · Posted Jul 2, 2015
- Contract value 100% obligated
- $298,743.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Madison, WI 53703, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $298,743 |
About this award
This federal contract award, valued at $298,743.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Salus Discovery LLC, a small business, under the Small Business Innovation Research (SBIR) program. The contract is for the project "THE MICROVOA: ENHANCING THE VIRAL OUTGROWTH ASSAY (VOA) WITH MICROTECHNOLOGY," which involves the research and development of innovative molecular diagnostic technologies for infectious diseases, particularly point-of-care nucleic acid testing solutions to improve the accuracy, accessibility, and affordability of diagnostic testing in resource-limited settings. Salus Discovery LLC is a for-profit limited liability company that specializes in developing diagnostic platforms for various infectious diseases, such as tuberculosis, sexually transmitted infections, and schistosomiasis. This contract award is part of the company's ongoing work with the NIAID and other National Institutes of Health programs to advance critical healthcare diagnostics.
Quick answers
Who was awarded contract HHSN272201600021C?
HHSN272201600021C was awarded to Salus Discovery LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 11, 2016.
How much is contract HHSN272201600021C worth?
The government has obligated $298,743 on HHSN272201600021C.
Was contract HHSN272201600021C competed?
The extent of competition for HHSN272201600021C was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award